Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated No phase listed Observational Accepts healthy volunteers

DWIBS-MRI: An Adjunct to the Traditional Diagnostic Breast Imaging Evaluation

ClinicalTrials.gov ID: NCT04491864

Public ClinicalTrials.gov record NCT04491864. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

1.1. Primary Objectives * To determine if MRI DWIBS can accurately identify suspicious lesions previously categorized on mammography and sonography as potentially malignant. * We will also validate whether DWIBS-MRI ADC values can be used to accurately differentiate benign from malignant lesions. Additionally, because it is not known whether tumor type or growth rate (Ki67 values) will affect our results, we will include these parameters in our analysis. * Once we validate the use of DWIBS-MRI ADC values to determine malignancy, can we establish an ADC threshold value to decrease the number of false positive biopsies that are performed while still maintaining a zero false negative rate? * This study will also assess the correlation between ADC values and the Ki-67 proliferative index of malignant lesions.

Study identification

NCT ID
NCT04491864
Recruitment status
Terminated
Study type
Observational
Phase
Not listed
Lead sponsor
Baylor Research Institute
Other
Enrollment
11 participants

Conditions and interventions

Conditions

Interventions

Not listed

Eligibility (public fields only)

Age range
30 Years and older
Sex
Female
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 11, 2019 (Actual)
Primary completion
Jul 1, 2022 (Actual)
Completion
Jul 1, 2022 (Actual)
Last update posted
Jan 26, 2026

2019 – 2022

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Baylor Scott & White Research Insitute Dallas Texas 75246 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04491864, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 26, 2026 · Synced Oct 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04491864 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →